Spago Nanomedical presented clinical data from its Phase I/IIa Tumorad-01 study at the ANZSNM 2026 conference, showing visible tumor uptake of its radiopharmaceutical ¹⁷⁷Lu-SN201 in patients with advanced head and neck cancers. These findings support the drug's mechanism of action and were deemed proof-of-concept by the study's Data Monitoring Committee. The study is progressing towards defining the recommended Phase II dose, which will enable further efficacy testing in selected tumors. This progress marks an important step in developing Tumorad as a new treatment for advanced solid tumors.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
